INS and Hyperglycemia: In contrast to daily rapamycin administration, which caused fasting hyperglycemia and hyperinsulinemia and impaired glucose‐stimulated insulin secretion (GSIS) from beta cells, intermittent (1×/5 days) rapamycin treatment did not impact fasting glucose and insulin levels, and had a minimal impact on GSIS (Fig. 2).